Table 2.
Baseline characteristics of study population.
| Variables | Value (n = 200) |
|---|---|
| Age, years | 63.18 ± 8.12 |
| Gender, male | 151 (75.5) |
| BMI, kg/m2 | 29.47 ± 5.08 |
| BMI 25–29.99 kg/m2 | 85 (42.5) |
| BMI ≥ 30 kg/m2 | 78 (39) |
| WHR | 0.95 ± 0.08 |
| WHR ≥ 0.85 women, ≥ 0.9 men | 167 (83.5) |
| LV ejection fraction, % | 52.24 ± 7.87 |
| LVMI BSA, g/m2 | 111.79 ±28.86 |
| LVMI height, g/m2.7 | 52.73 ± 14.52 |
| LAVI, mL/m2 | 25.03 ± 7.41 |
| Diastolic dysfunction of left ventricle, n | 77 (38.5) |
| NT-proBNP, pg/mL | 271.30 ± 406.65 |
| hs-TnT, pg/mL | 12.53 ± 11.78 |
| Creatinine, µmol/L | 86.57 ± 19.56 |
| GFR, mL/min/1.73m2 | 82.12 ± 22.49 |
| Total cholesterol, mg/dl | 159.42 ± 45.38 |
| Triglycerides, mg/dl | 130.63 ± 135.49 |
| High-density lipoprotein cholesterol, mg/dl | 52.06 ± 16.47 |
| Low-density lipoprotein cholesterol, mg/dl | 90.88 ± 37.20 |
| Low-density lipoprotein cholesterol ≥55 mg/dl, n | 177 (88.5) |
| Diabetes mellitus, n | 78 (39) |
| Smoking history, n | 148 (74) |
| Current smoking, n | 46 (23) |
| Use of ACE-I/ARB, n | 172 (86) |
| Use of beta-blockers, n | 176 (88) |
| Use of statin, n | 182 (91) |
The data is shown as n (%), mean ± SD. SD, standard deviation; BMI, body mass index; kg, kilogram; m2, square meter; WHR, waist to hip ratio; LV, left ventricle; LVMI, left ventricular mass index; BSA, body surface area; g, gram; LAVI, left atrial volume index; mL, millilitre; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-TnT, high-sensitivity troponin T; GFR, glomerular filtration rate Cockcroft–Gault Equation; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.